Clinical trials: WHIM
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
WHIM Syndrome
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with…
- Trial name
- NCT03995108
- Testing
- Mavorixafor
- Where
- 23 sites in United States, Australia and 11 more
- Volunteers
- 31 people
- Sponsor
- X4 Pharmaceuticals
WHIM Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not…
- Trial name
- NCT03087370
- Testing
- No intervention
- Sponsor
- X4 Pharmaceuticals
Large Reperfused ST-Elevation Myocardial Infarction
CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)
The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a stem cell mobilizing agent, on cardiac function and infarct size and on safety and tolerability, in patients with reperfused ST-Elevation…
- Trial name
- CATCH-AMI (NCT01905475)
- Testing
- POL6326
- Where
- 17 sites in Austria, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Polyphor Ltd.
Solid Tumor
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory…
- Trial name
- NCT02737072
- Testing
- LY2510924, Durvalumab
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.
- Trial name
- NCT01374503
- Testing
- ALX-0651
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
Healthy
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers
Phase I study to determine and compare the safety/tolerability of single ascending doses of POL6326 by intravenous infusion.
- Trial name
- NCT01841476
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Polyphor Ltd.
Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the…
- Conditions
- Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT01120457
- Testing
- BMS-936564 (Anti-CXCR4)
- Where
- 11 sites in United States
- Volunteers
- 96 people
- Sponsor
- Bristol-Myers Squibb
Neutropenia
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are…
- Trial name
- NCT06056297
- Testing
- Mavorixafor
- Where
- 114 sites in United States, Argentina and 23 more
- Volunteers
- 176 people
- Sponsor
- X4 Pharmaceuticals
WHIM Syndrome
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants…
- Trial name
- NCT03005327
- Testing
- X4P-001
- Where
- 2 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- X4 Pharmaceuticals
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
This is an international study of vicriviroc in 500 adult HIV-infected subjects who are failing standard antiretroviral therapy (ART). HIV must be of a certain type known as R5/X4-mixed tropic.
- Trial name
- NCT00243568
- Testing
- Vicriviroc
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus
The purpose of this study is to measure viral tropism over time in subjects with X4-tropic or non-phenotypeable virus while receiving standard of care therapy. This is an observational study.
- Trial name
- NCT00321438
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer).
- Trial name
- NCT01010880
- Testing
- BKT140
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- Biokine Therapeutics Ltd
Waldenstrom's Macroglobulinemia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to…
- Trial name
- NCT04274738
- Testing
- Mavorixafor, Ibrutinib
- Where
- 5 sites in United States, Greece
- Volunteers
- 16 people
- Sponsor
- X4 Pharmaceuticals
Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with…
- Trial name
- NCT02765165
- Testing
- USL311, Lomustine
- Where
- 6 sites in United States, Spain
- Volunteers
- 26 people
- Sponsor
- Proximagen, LLC
Neutropenia
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
This is a 2-part study of mavorixafor in participants diagnosed with chronic neutropenia. The main goal of Part 1 (Phase 1b) is to help researchers learn more about how the investigational medicine, mavorixafor, impacts people…
- Trial name
- NCT04154488
- Testing
- Mavorixafor
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- X4 Pharmaceuticals
Marginal Zone Lymphoma
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission…
- Trial name
- LYMFOR (NCT06125028)
- Testing
- [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose
- Where
- 12 sites in Austria, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Pentixapharm AG
HIV Infections, Human Immunodeficiency Virus
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients
This is a 28-day, multi-center, placebo-controlled study designed to look at the dose response, efficacy, and safety of SP01A, given as a pill to be swallowed, in the treatment of HIV-infected subjects.
- Trial name
- NCT00299897
- Testing
- SP01A
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Samaritan Pharmaceuticals, Inc